Equity Capital Markets

Aclaris Therapeutics, Inc.

10/26
.
Piper Sandler served as bookrunner for Aclaris Therapeutics on its October 2026 registered direct offering
Sub-Type
Follow-On Offering
Sub-Sector
Biopharma